Pharmacy Pearls: Aspirin for ASCVD Prevention- When to Start and Stop

August 31st, 2020 | Pharmacy Pearls•Cardiology

This edition of Pharmacy Pearls focuses on using low-dose aspirin for ASCVD prevention. We highlight when aspirin is indicated to reduce ASCVD risk, as well as when it might be appropriate to de-prescribe (stop) based on patient-specific criteria. An algorithm is included that providers can follow to determine whether their patients are eligible for low-dose aspirin and how to evaluate the safety of initiating/continuing aspiring based on the patient’s bleed risk.

As always, we welcome any questions or feedback you may have. Just email the Pharmacy Team.

Taking too long?

Reload document

Open in new tab

Download PDF [310.92 KB]

135 Corporate Woods, Suite 320
Rochester, New York 14623-1466

Phone: (585) 758-7823
Fax: (585) 424-1268

Website by:

This is not an offer to purchase or a solicitation of an offer to purchase any securities or interest in Accountable Health Partners, LLC (AHP). An offer will only be made by means of a confidential private placement memorandum and subscription agreement.

ABI Value	Interpretation	Recommendation
Greater than 1.4	Calcification/vessel hardening	Refer to vascular specialist
1.0 - 1.4	Normal	None
0.9 - 1.0	Acceptable	None
0.8 - 0.9	Some arterial disease	Treat risk factor
0.5 - 0.8	Moderate arterial disease	Refer to vascular specialist
Less than 0.5	Severe arterial disease	Refer to vascular specialist

Pharmacy Pearls: Aspirin for ASCVD Prevention- When to Start and Stop

Pharmacy Pearls: Aspirin for ASCVD Prevention- When to Start and Stop

GENERAL COVID-19 INFORMATION